Abstract：
Stroke is the leading cause of disability worldwide, yet there is currently no effective treatment available to mitigate its negative consequences. Pro-inflammatory cytokines, such as interleukin-1 (IL-1), are known to play a crucial role in exacerbating the aftermath of stroke. Thus, it is hypothesized that blocking inflammation and administering anti-inflammatory drugs at an optimal time and dosage may improve the long-term quality of life for stroke patients. This systematic review examines the effectiveness and safety of IL-1 receptor antagonist (IL-1Ra), commercially known as \"anakinra,\" in clinical studies involving the treatment of stroke patients. A comprehensive literature search was conducted until October 2023 to identify relevant studies. The search yielded 1403 articles, out of which 598 were removed due to duplication. After a thorough review of 805 titles and abstracts, 797 articles were further excluded, resulting in 8 studies being included in this systematic review. The findings from all the included studies demonstrate that IL-1Ra is safe for use in acute ischemic and hemorrhagic stroke patients, with no significant adverse events reported. Additionally, biomarkers, clinical assessments, serious adverse events (AEs), and non-serious AEs consistently showed more favorable outcomes in IL-1Ra receiving patients. Stroke elevates the levels of several inflammatory cytokines, however, administration of IL-1RA directly or indirectly modulates these markers and improves some clinical outcomes, suggesting a potential therapeutic benefit of this intervention.
摘要：
中风是全球残疾的主要原因，然而，目前没有有效的治疗方法来减轻其负面影响。促炎细胞因子，如白细胞介素-1（IL-1），众所周知，在加重中风的后果中起着至关重要的作用。因此，据推测,阻断炎症反应并在最佳时间和剂量给予抗炎药可能会改善卒中患者的长期生活质量.本系统评价了IL-1受体拮抗剂（IL-1Ra）的有效性和安全性。商业上称为“anakinra”，“在涉及中风患者治疗的临床研究中。直到2023年10月进行了全面的文献检索，以确定相关研究。搜索产生了1403篇文章，其中598个由于重复而被删除。经过对805个标题和摘要的全面审查，797篇文章被进一步排除在外，导致8项研究被纳入本系统综述。所有纳入研究的结果表明，IL-1Ra在急性缺血性和出血性中风患者中使用是安全的，没有报告重大不良事件。此外,生物标志物，临床评估，严重不良事件（AE），在接受IL-1Ra的患者中，非严重AE始终显示出更有利的结果。卒中提高了几种炎性细胞因子的水平，然而,IL-1RA的施用直接或间接调节这些标志物并改善一些临床结果，提示这种干预的潜在治疗益处。
